204 related articles for article (PubMed ID: 1697153)
1. [Bases on timing of combined modality of chemotherapy and immunotherapy].
Ogura T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1414-20. PubMed ID: 1697153
[TBL] [Abstract][Full Text] [Related]
2. [Tumoricidal biological response modifiers (BRM)].
Niitsu Y; Kohgo Y; Watanabe N
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1407-13. PubMed ID: 1697152
[TBL] [Abstract][Full Text] [Related]
3. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
4. Biologic therapy of melanoma with cytokines and lymphocytes.
Bear HD; Hamad GG; Kostuchenko PJ
Semin Surg Oncol; 1996; 12(6):436-45. PubMed ID: 8914208
[TBL] [Abstract][Full Text] [Related]
5. Locoregional immunochemotherapy in hepatocellular carcinoma.
Kountouras J; Boura P; Kouklakis G
Hepatogastroenterology; 2002; 49(46):1109-12. PubMed ID: 12143214
[TBL] [Abstract][Full Text] [Related]
6. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
[TBL] [Abstract][Full Text] [Related]
7. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
Lee K; O'Donnell RW; Cockett AT
J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
[TBL] [Abstract][Full Text] [Related]
8. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma.
Kimura H; Yamaguchi Y
Cancer; 1997 Jul; 80(1):42-9. PubMed ID: 9210707
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
[TBL] [Abstract][Full Text] [Related]
10. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
Garbe C
Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093
[TBL] [Abstract][Full Text] [Related]
12. [Receptor-mediated cancer therapy--tumoricidal cytokines, adoptive therapy of LAK, TIL].
Niitsu Y; Watanabe N; Kondo H; Kanisawa Y
Gan To Kagaku Ryoho; 1990 Jun; 17(6):1134-41. PubMed ID: 1693487
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
Schultz KR; Klarnet JP; Peace DJ; Cheever MA; Badger CC; Bernstein ID; Greenberg PD
Cancer Res; 1990 Sep; 50(17):5421-5. PubMed ID: 2386946
[TBL] [Abstract][Full Text] [Related]
14. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
Kedar E; Ben-Aziz R; Shiloni E
Isr J Med Sci; 1988; 24(9-10):494-504. PubMed ID: 3264551
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 2 in cancer therapy.
Testa U; Montesoro E; Bulgarini D; Samoggia P; Masciulli R; Habetswallner D; Carè A; Mariani G; Giannella G; Boccoli G
Ann Ist Super Sanita; 1990; 26(3-4):283-334. PubMed ID: 2091501
[TBL] [Abstract][Full Text] [Related]
16. [Recent trends in cancer treatment using cytokines].
Urushizaki I
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):897-905. PubMed ID: 2471455
[TBL] [Abstract][Full Text] [Related]
17. [Experimental study on the optimal treatment schedule for combination of BRM (immunostimulators, cultured killer cells or interleukin-2) and chemotherapy].
Kan N; Okino T; Satoh K; Mise K; Teramura Y; Yamasaki S; Harada T; Ohgaki K; Tobe T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1421-7. PubMed ID: 2389941
[TBL] [Abstract][Full Text] [Related]
18. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy.
Hong WS; Kim CM; Lee JO; Kang TW; Yun TK; Kim CY
Jpn J Clin Oncol; 1990 Mar; 20(1):87-93. PubMed ID: 2108272
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
20. IL-2/LAK cell treatment for advanced cancers with emphasis on a novel administration.
Auber ML; DeHaven JI; Raich PC; Rogers JS; Crowell EB; Romero P; Mahin EJ; Sosnowski JT; Lamm DL
W V Med J; 1991 Aug; 87(8):344-6. PubMed ID: 1949753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]